BR112021021062A2 - Compostos e métodos que alvejam tau humano - Google Patents

Compostos e métodos que alvejam tau humano

Info

Publication number
BR112021021062A2
BR112021021062A2 BR112021021062A BR112021021062A BR112021021062A2 BR 112021021062 A2 BR112021021062 A2 BR 112021021062A2 BR 112021021062 A BR112021021062 A BR 112021021062A BR 112021021062 A BR112021021062 A BR 112021021062A BR 112021021062 A2 BR112021021062 A2 BR 112021021062A2
Authority
BR
Brazil
Prior art keywords
methods
human tau
compounds
target human
tau
Prior art date
Application number
BR112021021062A
Other languages
English (en)
Inventor
Albert Driver David
L Dage Jeffrey
Jinbiao Chen
Edward Vaillancourt Peter
William Siegel Ii Robert
Fisher Hinton Steven
Xiyun Chai
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112021021062A2 publication Critical patent/BR112021021062A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

compostos e métodos que alvejam tau humano. a presente invenção fornece compostos e métodos que alvejam tau humano, particularmente tau humano fosforilado em treonina (217) e isoformas de tau expressas somente no cns, incluindo anticorpos terapêuticos, composições farmacêuticas e aplicações de diagnóstico úteis no campo de doenças neurodegenerativas, tais como ad, psp e ftd.
BR112021021062A 2019-05-31 2020-05-22 Compostos e métodos que alvejam tau humano BR112021021062A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855331P 2019-05-31 2019-05-31
PCT/US2020/034274 WO2020242963A1 (en) 2019-05-31 2020-05-22 Compounds and methods targeting human tau

Publications (1)

Publication Number Publication Date
BR112021021062A2 true BR112021021062A2 (pt) 2021-12-14

Family

ID=71083730

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021062A BR112021021062A2 (pt) 2019-05-31 2020-05-22 Compostos e métodos que alvejam tau humano

Country Status (12)

Country Link
US (1) US20220146535A1 (pt)
EP (1) EP3977135A1 (pt)
JP (2) JP7291250B2 (pt)
KR (2) KR102633666B1 (pt)
CN (1) CN113950625A (pt)
AU (2) AU2020283534B2 (pt)
BR (1) BR112021021062A2 (pt)
CA (1) CA3140201A1 (pt)
EA (1) EA202192888A1 (pt)
IL (1) IL287611A (pt)
MX (1) MX2021014473A (pt)
WO (1) WO2020242963A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
IL312045A (en) 2021-10-22 2024-06-01 Lilly Co Eli Combination therapy with O-GLCNACASE (OGA) inhibitors.
CN118525032A (zh) 2021-10-29 2024-08-20 伊莱利利公司 靶向白细胞介素34的化合物和方法
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
AU2022376940A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
ES2274869T3 (es) * 2000-01-24 2007-06-01 Innogenetics N.V. Diagnostico de tauopatias determinando la relacion tau/fosfotau.
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
SG10201703771WA (en) 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2014011972A1 (en) 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
KR101696061B1 (ko) * 2015-03-05 2017-01-13 재단법인 아산사회복지재단 퇴행성 뇌질환 진단에 적합한 이미지 바이오 마커를 획득하는 방법, 장치 및 이를 이용하여 퇴행성 뇌질환을 진단하는 방법
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
AU2024203048A1 (en) 2024-05-30
CN113950625A (zh) 2022-01-18
JP7291250B2 (ja) 2023-06-14
JP2023110033A (ja) 2023-08-08
EP3977135A1 (en) 2022-04-06
JP2022534759A (ja) 2022-08-03
EA202192888A1 (ru) 2022-03-23
KR20240019394A (ko) 2024-02-14
US20220146535A1 (en) 2022-05-12
IL287611A (en) 2021-12-01
AU2020283534B2 (en) 2024-05-16
CA3140201A1 (en) 2020-12-03
JP7544911B2 (ja) 2024-09-03
AU2020283534A1 (en) 2021-11-25
MX2021014473A (es) 2022-01-06
KR20220004118A (ko) 2022-01-11
WO2020242963A1 (en) 2020-12-03
KR102633666B1 (ko) 2024-02-06

Similar Documents

Publication Publication Date Title
BR112021021062A2 (pt) Compostos e métodos que alvejam tau humano
CO2021005987A2 (es) Compuestos de anillo fusionado
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CL2021000387A1 (es) Compuestos de anillo fusionado
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
MD3204025T2 (ro) Compoziții care conțin tulpini bacteriene
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
MD3209309T2 (ro) Compoziții care conțin tulpini bacteriene
MX2023002507A (es) Inhibidores de cd73.
EA201990400A1 (ru) Соединения и композиции и их применение
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
BR112018006873A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
EA202090414A1 (ru) Соединения и их применение
MX2020007628A (es) Composiciones y metodos de uso.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
BR112022000855A2 (pt) Moduladores de nlrp3
BR112022021743A2 (pt) Compostos e métodos direcionando a interleucina-34
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.